Join the Canadian SADS Foundation on November 19th, 2025, for an engaging webinar presented by Solid Biosciences, exploring the potential of gene therapy in treating Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

The session will highlight their investigational program with a focus on the ARTEMIS trial evaluating SGT-501 for CPVT. Attendees will learn about the promise of gene therapy for the CPVT community and gain insight into this upcoming clinical study.

Dr. Gabriel Books, MD, is the Chief Medical Officer at Solid Biosciences. He leads the company’s clinical development programs and brings expertise in advancing novel therapies for rare diseases through clinical research and regulatory strategy.

Seth Rotberg is the Senior Vice Manager of Patient Advocacy at Solid Biosciences. Drawing on his professional experience and personal perspective as a rare disease advocate, he works to ensure the patient voice is central to Solid’s work and to strengthen connections with patient communities worldwide.

We strongly encourage you to attend the live session to interact and pose questions. While a recording will be available for everyone post-event, participating live ensures that you can contribute to the discussion and get the most out of this educational opportunity. Please note that The Q&A session will not be recorded.